John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, briefly shares some updates from the Phase Ib KEYNOTE-013 trial (NCT01953692), which is evaluating the safety and efficacy of pembrolizumab in patients with Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.